

Subject Index

- A β .** *See* Amyloid β -protein
- Acetylcholine (ACh)
and APP secretion, 393–397
ChEI and, 393–394, 396
DHX-induced release of, 428–429
- Aging**
and AD-associated histopathological changes, 279
and AD onset, 148–149
 β -amyloidosis in, 388–392
HA in, 6–10
hippocampal pathology in, 2–3
lipid metabolite-membrane interactions and, 369
and memory, 3
and rCBF, 14–19
- ALS.** *See* Amyotrophic lateral sclerosis
- Alzheimer's disease (AD).** *See also* Dementia;
Familial Alzheimer's disease
 $A\beta$ mRNA expression in, 288–291
amyloid deposit components in, 282
amyloid fibril toxicity in, 89–94
 β -amyloidosis and, 388–392
anti-inflammatory drug therapy for, 213–219
apoE in, 139–143
apoE2 in, 49, 261–264
apoE3 in, 263–264
apoE4 in
and cholinergic dysfunction, 167–173
and neuropathological correlates, 158–161
and vascular lesions, 266–269
apoE alleles in
and AD susceptibility, 147–148
and age of onset, 148–149
and brain vascular pathology, 266–269
and neuropathological landmarks, 166–173
and NFT formation, 276–279
apoE genotype in
distribution of, 261–264
and neuropathological correlates, 158–162
APP misprocessing and, 175–177
APP overexpression and, 425
brain metabolism impairment and, 385–386
CDP-choline effects in, 399–403
cerebral amyloid angiopathy in, 298
ChAT activity in, 170–171, 197–203
cholinergic dysfunction in, 166–173, 388–392
cognitive training in, 249–253
diagnosis of
cross-sectional, 6–8
NIRS in, 22–27
drug therapy of, 177–180
genetic predisposition to, 158–162. *See also* Apolipoprotein E
glutamate cytotoxicity and, 356–361
HA and, 6–11
head injury and, 271–274
hippocampal anatomy in, 4–8
hippocampal pathology in, 2–3
IL-6 in, 205–211
immune response in, 214–217
M1-agonist treatment of, 189–194
memory in
auditory verbal short-term, 239–241
glucose metabolism during, 233–238
rCBF during, 233–241
visual vs. auditory, 233–238
neural cells model for, 415–419
neurobiology in, 30–35
neurofibrillary pathology of. *See also*
Neurofibrillary tangles
molecular mechanism of, 132–136
tau protein and, 121–129
therapeutic approach to, 136
neuroimaging studies in, 3–4, 30–35
NFT correlation with, 276–279
vs. non-fluent aphasia, 243–247
pathogenesis of
phospholipid metabolism and, 368–372
proteoglycans in, 316–319
perceptual disorders in
visual and spatial, 221–224
visual versus auditory memory, 233–238
PKC changes and, 332–336
plaque types in, 206–211
rCBF in, 239–241
smoking and, 392
tau protein and
microtubule interactions with, 96–103
phosphorylation of, 107–110
tau protein in, 121–129, 133–136
treatment for
besipirdine in, 410–414
CDP-choline in, 399–403
ChEI in, 393–397
HWA 285 in, 404–407
Amyloid fibril toxicity, 89–94
 β -Amyloidosis
and cholinergic dysfunction, 388–392
smoking and, 390–392
Amyloid precursor-like proteins (APLPs)
in mouse CNS, 78–80

- receptor processing of, 179
structure of, 282
- Amyloid precursor protein (APP)
ACh-induced formation of, 338–339
activity site within, 116–117
in AD, 58, 176–177
cell-surface receptors and, 178–179
in cellular signaling pathways, 114–118
ChEI and, 393–397
in cognitive function, 293–296
and corpus callosum agenesis, 72
in DS, 58
and FAD, 49–55
function of, 317
gene family of, 281–286
gene for
 and anti-A β protection, 303–308
 expression of, 74–75, 303–308
 mice deficient for, 421–425
 mutation effects, 425
 targeting of, 423–424
and impaired behavior, 65–71
MAPK stimulation by, 115–116
misprocessing of, 176–177
neurotrophic/neuroprotective effects of, 82–86
NF- κ B induction by, 305–308
pedigrees of, 50–51
processing of
 in AD, 176–177
 and A β formation, 58–63
 calcium regulation of, 329–330
 and dementia, 339
 and functional impairment, 177
 mGluRs regulation of, 338–342
 PKC regulation of, 327–329
 α -secretase and, 177–180
 β -secretase and, 178, 184–187
 therapeutic potential in, 177–180
protease complex with, 183–187
proteoglycan binding to, 317–319
secretion of, 178–179
 apo E regulation of, 322–325
 arachidonic acid-induced, 310–313
structure of, 114–115, 282
 and tau hyperphosphorylation, 117–118
 β -Amyloid precursor protein (β APP). *See*
 Amyloid precursor protein
- Amyloid β -protein (A β)
in AD, 58, 77–78, 288–301
altered expression of, 288–291
and amyloid fibril toxicity, 89–94
apoE and, 271–274, 276–279
APP misprocessing and, 176
and β APP cellular levels, 299–300
brain burden of
 as drug therapy target, 177–178
 reduction of, 178–180
cascade mechanism model, 300–301
cell death induced by, 293–296
in cerebral amyloid angiopathy, 300–301
in cerebrovascular cellular pathology, 297–301
in DS, 58
fibrillary toxicity of, 89–94
formation of, 58–63
 APP secretion and, 177
 PKC regulation of, 328–330
 receptor activation and, 179–180
 α -secretase and, 177–178, 180
 β -secretase and, 184
head injury and, 271–274
in HLSM cell degeneration, 298–299
and LDH activity, 170–172
MAB for, 344–354
neurotoxicity of, 362–365
 apoE2 and, 170
 APP protection against, 305–308
 free radicals in, 303–304, 362–365
 NF- κ B and, 303–304
- Amyotrophic lateral sclerosis (ALS), 385–386
- Aphasia, progressive non-fluent, 243–247
- APLP2. *See* Amyloid precursor-like proteins
- Apolipoprotein E (apoE)
and AD, 139–143. *See also*
 Apolipoprotein alleles;
 Apolipoprotein E2; Apolipoprotein E3; Apolipoprotein E4;
 Apolipoprotein genotype
biological role of, 140, 161–162
and cholinergic dysfunction, 166–173
and cytoskeletal organization, 141–143
and environmental stress, 154–155
knock-out mice construction, 152–154
in lipid metabolism, 140–143, 167
location of, 149–151
MAP2c interactions with, 151–152
and microtubular metabolism, 146–155
neurobiological role for, 161–162, 166–167
structure/function of, 139–143
synthesis of, 161, 167
tau interactions with, 151, 161
and tau phosphorylation, 152
- Apolipoprotein E2 (apoE2)
in AD, 49
 and age of onset, 148
 frequency of, 159, 262–263
and cell viability, 172
in dementia, 255–258
in DS, 255–258
incidence of, 158–159
protection conferred by, 49, 261–264
protective effect of, 49, 172, 264
and type III hyperlipoproteinemia, 140

- Apolipoprotein E3 (apoE3)
in AD, 262-264
and A β internalization, 173
in APP secretion regulation, 322-325
and cytoskeletal organization, 141-143
frequency of, 159
and neurite extension, 141-143
tau interaction with, 141
- Apolipoprotein E4 (apoE4)
and A β deposition, 140
in AD, 140, 261-264
neuropathological correlates, 159-161
pathophysiology, 267
as risk factor, 159, 167, 171
in APP secretion regulation, 322-325
and ChAT activity, 170-171
and ChAT loss, 392
in Creutzfeldt-Jakob disease, 267
and cytoskeletal organization, 141-143
and late onset AD, 140
and late onset FAD, 166-167, 261
in multi-infarct dementia, 267
and neurite extension, 141-143
neuropathological correlates of, 159-161
and NFT, 140-141
frequency of, 169-170
and tau hyperphosphorylation, 141
in vascular dementia, 267
- Apolipoprotein E (apoE) alleles
and AD susceptibility, 147-148, 260-264
and age of onset, 148-149
and brain vascular pathology, 266-269
and ChAT activity, 170-172
frequency in population, 158-159
- Apolipoprotein E (apoE) genotypes
in AD, 49, 158-162
and A β deposition, 271-274, 276-279
and AD susceptibility, 147-148, 266-269
and age of AD onset, 148-149
and brain vascular pathology, 266-269
incidence of, 139-140, 158-159
in head-injured patients, 272-274
and NFTs, 276-279
- Apolipoprotein E (apoE) receptors, 162
- β APP. *See* Amyloid precursor protein
- Arachidonic acid, in APP secretion, 310-313
- B**
- Besipirdine, in AD treatment, 410-414
- Blood-oxygen-level-dependent fMRI (BOLD-fMRI). *See also* Functional magnetic resonance imaging
in brain activation studies, 43-46
- Brain energy metabolism
BOLD-fMRI study of, 43-46
cellular mechanisms of, 374, 380, 384-385
- glucose utilization for, 381-385
activation-induced increase in, 380-384
corticosterone effects on, 376-378
functions of, 374-375
insulin and, 376-378
impairment-induced neurodegenerative disorders, 385-386
- C**
- Cell-surface receptors
and A β formation, 179-180
and APLP processing, 179
and APP^s secretion, 178-179
- Cellular signaling pathways, 114-118
- Cerebral amyloid angiopathy, 298
- Cerebral hemoglobin oxygenation. *See also*
Regional cerebral blood flow
in AD patients, 25-26
age-dependent changes in, 24-25
during cognitive function, 14-19
infrared spectroscopy monitoring of, 22-24, 26-27
- ChAT. *See* Choline acetyltransferase
- ChEI. *See* Choline esterase inhibitors
- CDP-Choline, therapeutic effects of, 399-403
- Choline acetyltransferase (ChAT). *See also*
Choline esterase inhibitors
in AD, 197-203
apoE and, 167, 170-171
apoE4 and, 392
brain levels of
age-related, 390
smoking and, 390-392
- Choline esterase inhibitors (ChEI)
and AD treatment, 394, 396-397
and APP secretion, 393-397
- Cholinergic dysfunction
in AD, 166-173
 β -amyloidosis and, 388-392
apoE and, 166-173
- Cognitive function. *See also* Memory;
Perception
APP in, 293-296
besipirdine effect on, 410-414
CDP-choline effect on, 399-403
cortical blood flow during, 14-19, 22-27
DHX and, 427-429
training in AD patients, 249-253
- Cortical blood flow. *See* Regional cerebral blood flow
- Creutzfeldt-Jakob disease, 267
- Cytokines. *See also* Interleukin-6
and APP expression, 74-75
and APP^s secretion, 178-179
- Cytoskeletal organization. *See also*
Microtubules
apoE and, 141-143

cellular signaling pathways and, 114–118
 microtubular metabolism and, 147–155
 tau protein and, 124–129

Dementia. *See also* Alzheimer's disease;
 Multi-infarct dementia; Primary
 degenerative dementia; Vascular
 dementia
 apoE genotype and, 255–258
 APP processing and, 339
 incidence of, 1–2
 Lewy body type, 392
 MRI studies of, 37–40
 PHFs in, 132
 prediction of, 8–9
 Diabetes, amyloid fibril toxicity in, 89–94
 Diffuse Lewy body disease, 267
 Dihydropyridine (DHP)
 and ACh release, 428–429
 and cognitive function, 427–429
 for Parkinson's disease, 427–428
 Down's syndrome (DS)
 as AD risk factor, 415
 apoE genotype and, 255–258
 APP in, 58
 APP overexpression and, 425
 cerebral amyloid angiopathy in, 298
 neural cell model for, 415

Familial Alzheimer's disease (FAD)
 A β in, 58
 apoE4 and, 166–167, 261
 APP pedigrees in, 49–51
 at-risk studies of, 52–55
 chromosome 14 pedigrees in, 51–52
 diagnosis of, 226–231
 early onset of, 49
 frequency of, 261
 hippocampus changes in, 226–231
 incidence of, 261
 late onset, 166–167, 261
 neuroimaging features of, 49–55
 fMRI. *See* Functional magnetic resonance
 imaging
 Free radicals, in A β neurotoxicity, 303–304,
 362–365
 Functional magnetic resonance imaging
 (fMRI). *See also* Blood-oxygen-level-
 dependent fMRI
 in AD study, 41–42
 for brain activation studies, 43–46
 in dementia evaluation, 40–41

Glutamate cytotoxicity
 and AD, 356–358
 nicotine effects on, 358–361

HA. *See* Hippocampal atrophy
 HF. *See* Hippocampal formation
 Hippocampal atrophy (HA)
 and AD, 6–11
 assessment of, 6–7
 CSF changes in, 4–6
 in FAD, 226–231
 in normal aging, 9–10
 predictive value of, 8–9
 Hippocampal formation (HF). *See*
 Hippocampus
 Hippocampus
 anatomy of. *See also* Hippocampal atrophy
 in AD, 2–3, 6–8
 in aging, 6–8
 in at-risk patients, 10–11
 and incipient dementia, 8–9
 MRI determination of, 10–11
 neuroimaging studies of, 4–6
 changes in, 226–231
 and memory, 3
 HLSM. *See* Human leptomenigeal smooth
 muscle
 Human leptomenigeal smooth muscle
 (HLSM)
 A β -induced degeneration of, 298–299
 BAPP levels in, 299–300
 Huntington's disease, 385–386
 HWA 285 (Propentofylline), in dementia
 therapy, 404–407
 Hyperlipoproteinemia, type III, 140
IL-6. *See* Interleukin-6
 Interleukin-6. *See also* Cytokines
 Interleukin-6 (IL-6), in AD, 205–211
MAb. *See* Monoclonal antibodies
 Magnetic resonance imaging (MRI). *See also*
 Functional magnetic resonance
 imaging
 in dementia studies, 37–40
 in FAD diagnosis, 226–231
 in hippocampal volume loss
 determination, 10–11
 Magnetic resonance spectroscopy (MRS)
 of AD, 38–40
in vivo studies by, 37–38
 M1 Agonists. *See* M1 Muscarinic receptors
 M1 agonists. *See* M1 Muscarinic receptors
 MAP. *See* Microtubule-associated protein
 MAPK. *See* Microtubule-associated protein
 kinase
 Memory. *See also* Cognitive function
 in AD patients, 3
 rCBF and, 239–241
 recognition task performance, 233–238
 verbal short term, 239–241
 visual vs. auditory, 233–238

- aging and, 3, 14-19
 in brain activation studies, 44-46
 hippocampal lesions and, 3
 PET imaging of, 239-241
 rCBF during, 14-19, 239-241
- Metabotropic glutamate receptors
 (mGluRs), in APP processing,
 338-342
- mGluRs. *See* Metabotropic glutamate receptors
- Microtubule-associated protein (MAP). *See*
 Tau protein
- Microtubule-associated protein kinase
 (MAPK). *See also* Protein kinases
 APP stimulation of, 115-116
 in tau phosphorylation, 101-103,
 117-118
- Microtubules
 apoE and, 147
 apoE3 and, 142-143
 metabolism of, 146-155
 tau interaction with
 and neurite outgrowth, 99
 phosphorylation effect on, 101
 and tubule stabilization, 99-101, 103
- MID. *See* Multi-infarct dementia
- M1 Muscarinic receptors (m1AChRs)
 in AD treatment, 189-194
 and tau phosphorylation, 190, 192, 194
- Monoclonal antibody (MAb)
 for A β , 344-354
 for PHF-tau, 118
- MRI. *See* Magnetic resonance imaging
- MRS. *See* Magnetic resonance spectroscopy
- Multi-infarct dementia (MID), 404-407. *See also*
 Vascular dementia
 apoE4 in, 267
- N**ear infrared spectroscopy (NIRS), in
 AD diagnosis, 22-27
- Neurite extension
 apoE and, 141-143
 tau-microtubule interaction and, 99
- Neurofibrillary lesions. *See* Neurofibrillary
 tangles
- Neurofibrillary tangles (NFT). *See also*
 Paired helical filaments
 and AD, 121, 126, 128-129, 276-279
 apoE4 and, 140-141, 276-279
 molecular mechanism of, 132-136
 tau protein and, 121-129
 therapeutic approach to, 136
- Neuroimaging. *See also* Magnetic resonance
 imaging
 in AD and dementia studies, 3-4, 30-35
 BOLD-fMRI usefulness in, 43-46
 and FAD diagnosis, 49-55
 fMRI technique, 40-42
 MRS mapping, 37-40
- NF- κ B transcription factor (NF- κ B)
 A β activation of, 304
 APP induction of, 305-308
- NFT. *See* Neurofibrillary tangles
- NIRS. *See* Near infrared spectroscopy
- P**aired helical filaments (PHFs). *See also*
 Neurofibrillary tangles; Tau protein
 in AD, 97-98, 132-135
 assembly of, 98-99
 in neurofibrillary lesions, 121-129
 structural features of, 97
- Parkinson's disease, 427-428
- PDD. *See* Primary degenerative dementia
- Perception. *See also* Cognitive function
 disorders in AD, 233-238
 rCBF during, 16-17
- PET. *See* Positron emission tomography
- PHF. *See* Paired helical filaments
- Phospholipid metabolites. *See*
 Phosphomonoesters
- Phosphomonoesters (PME). *See also* L-
 Phosphoserine
 in AD brain tissue, 369
- L-Phosphoserine (L-PS). *See also*
 Phosphomonoesters
 membrane interactions with
 and AD pathophysiology, 372
 cholesterol content and, 370-371
 and lipid bilayer, 371-372
- Pick's disease, 247
- PKC. *See* Protein kinase C
- Plaques
 in AD, 166-173, 206-211
 apoE polymorphism and, 276-279
 IL-6 in, 205-211
- Positron emission tomography (PET),
 239-241
- Primary degenerative dementia (PDD), 404.
See also Alzheimer's disease
- Proteases. *See also* Secretases
 and APP, 183-187
 characterization of, 186-187
- Protein kinase C (PKC)
 and A β production, 328-330
 and AD, 332-336
 and APP processing, 327-329
 and APP release, 340-341
 and β APP secretion, 332-336
- Protein kinases. *See also* Microtubule-
 associated protein kinase
 in tau phosphorylation, 108-110,
 135-136
- Proteoglycans
 APP binding to, 317-319
 and pathogenesis of AD, 319

Regional cerebral blood flow (rCBF). *See also* Cerebral hemoglobin oxygenation in AD, 239–241
age-related changes in, 14–19
during cognitive function, 14–19, 22–27
during memory, 14–19, 233–238

α -Secretase
and APP degradation, 59, 184
in APP secretion, 177–178
and reduced A β formation, 177–178, 180

β -Secretase
and A β formation, 57, 59–61, 178, 180, 184
criteria for, 186
protease inhibition of, 178

Smoking
and AD, 392
and β -amyloidosis, 390–392

Tau protein. *See also* Microtubule-associated protein; Neurofibrillary pathology
apoE3 interactions with, 141, 151–154

hyperphosphorylation of
and AD, 107–110
APP and, 117–118
inactivation by, 141
and PHFs, 98
microtubule interactions with, 99–103, 141
molecular biology of, 96–98, 122–124
and neurofibrillary AD pathology, 121–129
and neurofibrillary degeneration, 133–136
and PHFs, 97–98, 107–110, 124–129
phosphorylation of, 101–104
apoE and, 141
m1AChRs and, 190, 192, 194
MAPK and, 108, 110
and PHF formation, 107–110
regulation of, 107–110
and tau-microtubule interactions, 101
structure of, 96–97

VaD. *See* Vascular dementia
Vascular dementia (VaD), 404–407
apoE4 in, 267

Index of Contributors

Abraham, C. R., 82-88
 Abraham, C. R., 183-188
 Aguzzi, A., 65-73
 Akaike, A., 356-361
 Aleva, K., 239-242
 Alvarez, X. A., 399-403
 Amaducci, L., 260-265

Barg, Y., 189-196
 Barger, S. W., 303-309
 Basaric-Keys, J., 322-326
 Battaini, F., 332-337
 Bauer, J., 205-212
 Becker, J. T., 239-242
 Beffert, U., 166-174
 Behr, D., 74-76
 Bergamaschi, S., 332-337
 Berger, M., 205-212
 Besipirdine Study Group, 410-414
 Beyreuther, K., 74-76, 281-287, 316-321
 Bianchetti, A., 221-225, 332-337
 Biernat, J., 96-106
 Binetti, G., 221-225, 332-337
 Bissette, G., 197-204
 Bobinski, M., 1-13
 Bohl, J., 276-280
 Brandeis, R., 189-196
 Brandner, S., 65-73
 Briggs, M., 158-165
 Bushnell, A., 344-355
 Buxbaum, J. D., 327-331

Caamaño, J., 399-403
 Cacabelos, R., 399-403
 Canter, R., 322-326
 Cappa, S. F., 221-225, 243-248
 Carroll, R. T., 310-315
 Chang, T., 183-188
 Chen, H. Y., 421-426
 Chung, H., 158-165
 Citron, M., 57-64
 Clariss, H., 316-321
 Cohen, D. L., 266-270
 Conner, M. W., 421-426
 Convit, A., 1-13
 Court, J. A., 388-392
 Cox, A. J., 338-343
 Cristina, N., 65-73
 Crook, R., 255-259

Davis, R. E., 310-315
 Davis-Salinas, J., 297-302
 Day, K., 255-259
 De Leon, M. J., 1-13

De Santi, S., 1-13
 Dekosky, S. T., 239-242
 Dirnagl, U., 22-29
 Doyle, P. D., 310-315
 Drewes, G., 96-106
 Dudley, D. T., 310-315
 Dunnett, S. B., 415-420
 Dyer, R. D., 310-315

Einstein, G., 146-157
 Emmerling, M. R., 310-315

Fazio, F., 243-248
 Fernández-Novoa, L., 399-403
 Fisher, A., 189-196
 Forleo, P., 260-265
 Fox, N. C., 226-232
 Frackowiak, R. S. J., 49-56
 Franco-Maside, A., 399-403
 Frederiksen, K., 415-420

George A. E., 1-13
 Ghaemi, M., 233-238
 Giacobini, E., 393-398
 Gilbert, J., 146-157
 Ginzburg, I., 189-196
 Goedert, M., 121-131, 146-157
 Golomb, J., 1-13
 Gómez, M. J., 399-403
 Gomez-Isla, T., 158-165
 González, R. G., 37-48
 Govoni, S., 332-337
 Grady, C. L., 14-21
 Graham, D. I., 271-275
 Graham, P., 344-355
 Greenberg, S., 114-120
 Greengard, P., 327-331
 Griffiths, M. H., 388-392
 Groß, W., 276-280
 Growdon, J. H., xi-xii, 158-165, 175-182
 Grundke-Iqbal, I., 132-138
 Gschwind, M., 293-296
 Gurwitz, D., 189-196
 Gustke, N., 96-106

Haass, C., 57-64
 Han, S.-H., 146-157
 Hardy, J., 255-259
 Haring, R., 189-196
 Heckerlen, H., 22-29
 Heiss, W. D., 233-238
 Heldman, E., 189-196
 Henneberg, N., 374-379
 Herholz, K., 233-238

- Hesse, L., 74-76
 Hock, C., 22-29, 249-254
 Hodges, D. B., Jr., 427-430
 Hofmann, M., 22-29, 249-254
 Hopkins, R., 421-426
 Hoyer, A., 374-379
 Huang, D., 146-157
 Huber, G., 293-296
 Huff, F. J., 410-414
 Hulette, C., 146-157
 Hüll, M., 205-212
 Hyman, B. T., 158-165
- I**nce, C., 1-13
 Iqbal, K., 132-138
- J**agust, W. J., 30-36
 Jiang, M., 421-426
 Jimenez, J., 338-343
 Johnson, M., 388-392
- K**alaria, R. N., 266-270, 288-292
 Karton, Y., 189-196
 Kennedy, A. M., 49-56
 Kessler, J., 233-238
 Khin-Nu, C., 255-259
 Kimura, J., 356-361
 Kirca, M., 276-280
 Kitt, C. A., 77-81
 Kittner, B., 404-409
 Klimowski, S., 189-196
 Knapp, S., 374-379
 König, G., 344-355
 Koo, E. H., 57-64
 Korczyn, A. D., 189-196
 Kosik, K. S., 114-120
 Kumar, U., 362-367
- L**abs, K.-H., 404-409
 Lai, C.-C., 393-398
 Lannert, H., 374-379
 Lee, R. K. K., 338-343
 Lee, V. M.-Y., 107-113
 Levesque, T. R., 427-430
 Li, Y., 322-326
 Li, Z.-W., 65-73
 Lipp, H.-P., 65-73
 Lloyd, S., 388-392
 Locke, K. W., 427-430
 Lorenzo, A., 89-95
- M**agistretti, C. P. J., 380-387
 Magni, E., 221-225
 Mahley, R. W., 139-145
 Mandelkow, E., 96-106
 Mandelkow, E.-M., 96-106
 Mann, D., 255-259
- Marciano, D., 189-196
 Martin, E., 374-379
 Martin, J. R., 293-296
 März, W., 276-280
 Masliah, E., 82-88, 146-157
 Mason, R. P., 368-373
 Masters, C. L., 74-76, 281-287, 316-321
 Mattson, M. P., 303-309
 McGeer, E. G., 213-220
 McGeer, P. L., 213-220
 Meshulam, H., 189-196
 Messa, C., 243-248
 Mielke, R., 233-238
 Miller, D., 1-13
 Mintun, M. A., 239-242
 Miozzo, A., 243-248
 Mönning, U., 74-76
 Moreau, J.-L., 293-296
 Mori, F., 393-398
 Mucke, L., 82-88
 Müller, U., 65-73
 Müller-Spahn, F., 22-29, 249-254
 Multhaup, G., 74-76
- N**acmias, B., 260-265
 Nathan, B. P., 139-148
 Nemeroff, C. B., 197-204
 Nichols, T., 239-242
 Nicoll, J. A. R., 271-275
 Nitsch, R. M., 175-182
 Nurcombe, V., 316-321
- O**hm, T. G., 276-280
 Owen, F., 255-259
- P**adovani, A., 221-225
 Pellerin, L., 380-387
 Perani, D., 243-248
 Pericak-Vance, M. A., 146-157
 Perlmuter, L. S., 344-355
 Perry, E. K., 388-392
 Perry, R., 255-259, 388-392
 Pettegrew, J. W., 368-373
 Piacentini, S., 260-265
 Pickering-Brown, S., 255-259
 Piggott, M. A., 388-392
 Pinkas-Kramarski, R., 189-196
 Pitas, R. E., 139-145
 Pittel, Z., 189-196
 Podlisny, M. B., 57-64
 Poirier, J., 166-174
 Premkumar, D. R. D., 266-270, 288-292
 Price, D. L., 77-81
- Q**iu, W. Q., 114-120

- R**acchi, M., 332-337
 Ragbavan, R., 255-259
 Rebeck, G. W., 158-165
 Reed, G., 316-321
 Reed, R. R., 77-81
 Richards, S. J., 415-420
 Richardson, J. S., 362-367
 Roberts, G. W., 255-259, 271-275
 Roscs, A. D., 146-157
 Rößner, M., 404-409
 Rossor, M. N., 49-56, 226-232
 Rother, M., 404-409
 Royston, M. C., 255-259
 Rudolphi, K., 404-409
 Rülcke, T., 65-73
 Rusinck, H., 1-13
- S**adof, E., 189-196
 Sandage, B. W., Jr., 427-430
 Sandberg, B. E. B., 415-420
 Sandbrink, R., 74-76, 281-287
 Saporito-Irwin, S. M., 297-302
 Saunders, A. M., 146-157
 Scharnagl, H., 276-280
 Schmechel, D. E., 146-157
 Schuh-Hofer, S., 22-29
 Schweers, O., 96-106
 Seidler, F. J., 197-204
 Selkoe, D. J., 57-64
 Shimohama, S., 356-361
 Sirinathsinghji, D. J. S., 421-426
 Sisodia, S. S., 77-81, 421-426
 Slotkin, T. A., 197-204
 Slunt, H. H., 77-81, 421-426
 Small, D. H., 74-76, 316-321
 Sorbi, S., 260-265
 Spurden, D., 388-392
 Steele, T. D., 427-430
 Stevens, J. M., 226-232
 Stevens, K. A., 421-426
 Strittmatter, W. J., 146-157
 Sunderland, T., 322-326
- T**arshish, C., 1-13
 Teplow, D. B., 57-64
- Thinakaran, G., 77-81
 Thorpe, A., 415-420
 Trabucchi, M., 221-225, 332-337
 Treves, T. A., 189-196
 Trinczek, B., 96-106
 Trumbauer, M. E., 421-426
 Trumbore, M. W., 368-373
 Turner, J., 388-392
 Tyner, S., 255-259
- V**an der Ploeg, L. H. T., 421-426
 Van Nostrand, W. E., 297-302
 Vanderputten, D., 322-326
 Verchovsky, R., 189-196
 Villringer, A., 22-29
 Villringer, K., 22-29
 Vogel, Z., 189-196
 Volk, B., 205-212
 von Koch, C. S., 77-81
- W**arrington, E. K., 226-232
 Waters, J., 415-420
 Webster, S., 344-355
 Weisgraber, K. H., 146-157
 Weissman, C., 65-73
 Wenzel, R., 22-29
 West, H., 158-165
 Williamson, T., 316-321
 Wiseman, M. B., 239-242
 Wisniewski, H., 1-13
 Wolfer, D. P., 65-73
 Wolozin, B. L., 322-326
 Wunderlich, D., 344-355
 Wurtman, R. J., 175-182, 338-343
- X**i, P.-T., 146-157
- Y**amazaki, T., 57-64
 Yankner, B. A., 89-95
- Z**heng, H., 77-81, 421-426
 Zhou, Y., 362-367